Centessa Pharmaceuticals plc - ADR CNTA

NAS: CNTA | ISIN: US1523091007   13/08/2025
17,14 USD (+0,18%)
(+0,18%)   13/08/2025
Grafiek Centessa Pharmaceuticals plc - ADR Grafiek Centessa Pharmaceuticals plc - ADR

Centessa Pharmaceuticals plc - ADR in het nieuws

12 augustus 2025 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 · Persbericht

16 juni 2025 · Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year · Persbericht

14 mei 2025 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 · Persbericht

24 maart 2025 · Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 · Persbericht

12 november 2024 · Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update · Persbericht

13 september 2024 · Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares · Persbericht

11 september 2024 · Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares · Persbericht

10 september 2024 · Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers · Persbericht

27 augustus 2024 · Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) · Persbericht

13 augustus 2024 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 · Persbericht

Mijn selecties